Skip to main content
Skip to section navigation
Skip to footer
Maravai LifeSciences
Main Menu
Contact
Search
About
Show submenu
About Maravai
Leadership
Board of Directors
Innovation
Supply Chain
Operations
Diversity, Equity, and Inclusion
Brands
Show submenu
Our Brands
TriLink BioTechnologies
Cygnus Technologies
Glen Research
Alphazyme
Impact
Show submenu
Our Impact
Maravai Foundation
Insights
Show submenu
Our Insights
Maravai Insights
From the Science and Innovation Office
Latest news
Investors
Show submenu
Overview
News & Events
Company Info
Financial Info
Stock Data
SEC Filings
ESG
Governance
Careers
Show submenu
Be a #MiracleMaker
Current Openings
Benefits and Growth
Culture and People
All SEC filings
Investors
Investors
Overview
News & Events
Press Releases
IR Calendar
Presentations
Email Alerts
R&D Day 2023
Company Info
Company Profile
Leadership
Annual Reports & Proxy
Contacts
FAQ
Financial Info
Financial Results
Income Statement
Balance Sheet
Cash Flow
Stock Data
Quote and Chart
Historical Data
Analyst Coverage
SEC Filings
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
ESG
Governance
Overview
Board of Directors
Board Committees
Governance Documents
Whistleblower Policy
Filing type:
View All
10-K
10-Q
144
3
4
4/A
424B4
5
8-A12B
8-K
ARS
CERT
CORRESP
DEF 14A
DRS
DRS/A
DRSLTR
EFFECT
PRE 14A
S-1
S-1/A
S-1MEF
S-8
SC 13G
SC 13G/A
UPLOAD
Year:
View All
2024
2023
2022
2021
2020
Date
Form
Description
PDF
XBRL
Pages
10/29/20
CORRESP
A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
5
10/29/20
S-1
General form of registration statement for all companies including face-amount certificate companies
Documents
expand_more
EX-10.2
EX-10.3
EX-10.4
EX-10.5
EX-10.6
EX-10.13
EX-10.14
EX-10.15
EX-10.16
EX-10.17
EX-10.18
EX-10.19
EX-10.20
EX-10.21
EX-10.22
EX-10.23
EX-10.24
EX-10.25
EX-23.1
EX-23.2
1277
10/28/20
UPLOAD
SEC-generated letter
Documents
expand_more
TEXT-EXTRACT
2
10/23/20
DRSLTR
Correspondence Related to Draft Registration Statement
5
10/23/20
DRS/A
Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy
Documents
expand_more
EX-10.24
475
10/21/20
UPLOAD
SEC-generated letter
Documents
expand_more
TEXT-EXTRACT
2
10/14/20
DRSLTR
Correspondence Related to Draft Registration Statement
14
10/14/20
DRS/A
Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy
Documents
expand_more
EX-10.2
EX-10.3
EX-10.4
EX-10.5
EX-10.6
EX-10.13
EX-10.14
EX-10.15
EX-10.16
EX-10.17
EX-10.18
EX-10.19
EX-10.20
EX-10.21
EX-10.22
EX-10.23
1014
10/08/20
UPLOAD
SEC-generated letter
Documents
expand_more
TEXT-EXTRACT
4
09/08/20
DRS
Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy
257
rss_feed
Filing RSS
Previous Page
arrow_back
Page
1
…
Page
20
Page
21
Page
22
Page
23
Page
24
Page
25
Page
26
Page
27
Page
28
Page
29
Select a page:
Page 1
Page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
Page 10
Page 11
Page 12
Page 13
Page 14
Page 15
Page 16
Page 17
Page 18
Page 19
Page 20
Page 21
Page 22
Page 23
Page 24
Page 25
Page 26
Page 27
Page 28
Page 29
Email Alerts
Company Profile
Contacts
RSS News Feed